Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2 and cancer therapy.

B W Hancock1, R C Rees

  • 1Department of Clinical Oncology, University of Sheffield Medical School, UK.

Cancer Cells (Cold Spring Harbor, N.Y. : 1989)
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.

European journal of cancer (Oxford, England : 1990)·2019
Same author

Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?

European journal of obstetrics, gynecology, and reproductive biology·2019
Same author

Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database.

Gynecologic oncology·2018
Same author

Classification systems in Gestational trophoblastic neoplasia - Sentiment or evidenced based?

Cancer treatment reviews·2017
Same author

Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.

Gynecologic oncology·2016
Same author

Late spontaneous resolution of persistent molar pregnancy.

BJOG : an international journal of obstetrics and gynaecology·2016
Same journal

Epithelial cell plasticity in neoplasia.

Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Same journal

Uptake of low-density lipoprotein by malignant cells--possible therapeutic applications.

Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Same journal

Some thoughts on the cytolytic mechanism of natural killer lymphocytes.

Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Same journal

JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine.

Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Same journal

A role for cholinesterases in tumorigenesis?

Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Same journal

The soluble interleukin-2 receptor as a marker for human neoplasia and immune status.

Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
See all related articles

Interleukin-2 (IL-2) research shows progress in understanding its molecular biology and function. However, challenges remain in its clinical application for cancer immunotherapy, with most patients not responding to IL-2 treatment.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Interleukin-2 (IL-2) is a cytokine crucial for immune responses.
  • Significant advancements have been made in understanding IL-2 and its receptors.
  • Current knowledge gaps exist regarding IL-2's intracellular signaling and responsive lymphocyte subpopulations.

Purpose of the Study:

  • To provide an overview of state-of-the-art research on Interleukin-2 (IL-2).
  • To identify key areas requiring further investigation for effective IL-2-based cancer immunotherapy.

Main Methods:

  • Review of current research findings on IL-2.
  • Discussion of preclinical and clinical data related to IL-2 therapy.

Main Results:

Related Experiment Videos

  • IL-2 research has elucidated its molecular biology and receptor functions.
  • T cells and Large Granular Lymphocytes (LGLs) can mediate tumor cell killing.
  • Preclinical studies show IL-2 can induce tumor regression, but clinical translation is limited.

Conclusions:

  • Further research is needed to understand IL-2's intracellular signaling pathways.
  • Detailed study of lymphocyte subpopulations responding to IL-2 is essential.
  • Elucidating the mechanisms of IL-2-mediated antitumor effects in vivo is critical for improving clinical outcomes in cancer immunotherapy.